Glucocorticoid Receptor Antagonism Augments Fluoxetine-Induced Downregulation of the 5-HT Transporter

Abstract

The effects of combined treatment with a glucocorticoid receptor (GR) antagonist, Org 34850, and a selective serotonin reuptake inhibitor (SSRI), fluoxetine, were investigated on pre-and postsynaptic aspects of 5-HT neurotransmission. Rats were treated for 14 days with Org 34850 (15 mg per kg per day subcutaneously), fluoxetine (10 mg per kg per day intraperitoneally), or a combination of both drugs.[3 H]-citalopram binding (an index of 5-HT transporter (5-HTT) expression) was only slightly affected by Org 34850 alone: decreased in cortex and midbrain and increased in hippocampus. In contrast, chronic fluoxetine markedly decreased 5-HTT levels in all regions. Importantly, this decrease was significantly enhanced by combined Org 34850/fluoxetine treatment. There were no changes in the expression of 5-HTT mRNA, suggesting these effects were not due to changes in gene transcription. Expression of tryptophan hydroxylase mRNA and both 5-HT 1A autoreceptor mRNA and protein (assessed using [3 H]-8-OH-DPAT binding) were unchanged by any treatment. The expression of postsynaptic 5-HT 1A receptor protein in the forebrain was unaltered by fluoxetine, Org 34850 or the combined Org 34850/fluoxetine treatment. This downregulation of 5-HTT by fluoxetine and its enhancement by Org 34850 can explain our recent observation that GR antagonists augment the SSRI-induced increase in extracellular 5-HT. In addition, these data suggest that the augmentation of forebrain 5-HT does not result in downregulation of forebrain 5-HT 1A receptor expression. Given the importance of 5-HT 1A receptor-mediated transmission in the forebrain to the antidepressant response, these data indicate that co-administration of GR antagonists may be effective in augmenting the antidepressant response to SSRI treatment.

Mineralocorticoid receptor antagonist spironolactone prevents chronic corticosterone induced depression-like behavior

“…Further, co-administration of a GR antagonist could potentiate the anti-depressant effect of SSRI (Johnson et al, 2009). Together, these studies highlight the intimate relationship between hyperactivity of HPA axis and 5-HT adjustment in management of depression.…”

Subacute administration of fluoxetine prevents short-term brain hypometabolism and reduces brain damage markers induced by the lithium-pilocarpine model of epilepsy in rats

“…For the present study, the dose and duration of fluoxetine administration (10 mg/kg/day × 7 days) was chosen on the basis of the numerous pharmacological and neurochemical effects published (Lauzurica et al, 2013;Hrdina and Vu, 1993;Johnson et al, 2009), including an inhibitory effect on hippocampal seizures elicited by electrical stimulation in rats (Wada et al, 1995). As shown in Fig.…”

The acid sphingomyelinase inhibitors block interferon-α-induced serotonin uptake via a COX-2/Akt/ERK/STAT-dependent pathway in T cells

“…Current studies indicate that it also alters 5-HTT density and expression [19,[67][68][69][70]. In addition, chronic fluoxetine administration inhibits ERK1/2 phosphorylation in the rat brain [71], while inhibiting the ERK1/2 pathway mimics the function of an antidepressant [72].…”